| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8615983 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 9 Pages |
Abstract
Our results show that carriership of PSMB1 rs12717 minor allele is predictive for suboptimal response with bortezomib treatment, which could be explained by less active proteasomes that are less sensitive to bortezomib, and myeloma cells consequently relying on other escape mechanisms to cope with the abundance of misfolded proteins.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Gergely Varga, Gábor Mikala, Katalin Piroska Kiss, Ãva Kosóczki, Edit Szabó, Nóra Meggyesi, Katalin Balassa, Petra Kövy, Bálint Tegze, Gergely Szombath, Attila Tordai, Hajnalka Andrikovics, László Homolya, Tamás Masszi,